DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

Phase 1

Recruiting

Conditions: Healthy Volunteer

Interventions: Drug: ABBV-701
Drug: Placebo

First Posted Date: 2025-03-26

Last Posted Date: 2025-04-15

Lead Sponsor: AbbVie

Target Recruit Count: 58

Registration Number: NCT06895343

Locations: 🇺🇸
Acpru /Id# 273354, Grayslake, Illinois, United States

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

Phase 1

Recruiting

Conditions: Healthy Volunteer

Interventions: Drug: Tavapadon

First Posted Date: 2025-03-26

Last Posted Date: 2025-04-08

Lead Sponsor: AbbVie

Target Recruit Count: 84

Registration Number: NCT06895356

Locations: 🇺🇸
Acpru /Id# 275870, Grayslake, Illinois, United States

A Study to Assess Safety and Effectiveness of Injections of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Change of Mid-Face Volume

Phase 3

Recruiting

Conditions: Mid Face Volume Deficit

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-28

Lead Sponsor: AbbVie

Target Recruit Count: 231

Registration Number: NCT06734351

Locations: 🇺🇸
Westlake Dermatology & Cosmetic Surgery - Westlake /ID# 258156, Austin, Texas, United States
🇺🇸
Skin Research Institute LLC /ID# 258158, Coral Gables, Florida, United States
🇺🇸
Pure Dermatology /ID# 258168, Metairie, Louisiana, United States

and more 1 locations

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Phase 1

Not yet recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Etentamig
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Daratumumab
Drug: Carfilzomib

First Posted Date: 2025-03-24

Last Posted Date: 2025-04-24

Lead Sponsor: AbbVie

Target Recruit Count: 440

Registration Number: NCT06892522

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Phase 2

Not yet recruiting

Conditions: Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Neoadjuvant

Interventions: Drug: Carboplatin
Drug: Mirvetuximab Soravtansine

First Posted Date: 2025-03-24

Last Posted Date: 2025-03-24

Lead Sponsor: AbbVie

Target Recruit Count: 140

Registration Number: NCT06890338

A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants

Phase 1

Recruiting

Conditions: Healthy Volunteer

Interventions: Drug: ABBV-101

First Posted Date: 2025-03-20

Last Posted Date: 2025-04-23

Lead Sponsor: AbbVie

Target Recruit Count: 16

Registration Number: NCT06887010

Locations: 🇺🇸
Acpru /Id# 275921, Grayslake, Illinois, United States

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

Phase 3

Not yet recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Risankizumab
Drug: Vedolizumab

First Posted Date: 2025-03-18

Last Posted Date: 2025-05-21

Lead Sponsor: AbbVie

Target Recruit Count: 530

Registration Number: NCT06880744

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

Phase 2

Recruiting

Conditions: Psoriatic Arthritis

Interventions: Drug: Risankizumab
Drug: Lutikizumab

First Posted Date: 2025-03-07

Last Posted Date: 2025-05-13

Lead Sponsor: AbbVie

Target Recruit Count: 120

Registration Number: NCT06865105

Locations: 🇺🇸
Newport Huntington Medical Group /ID# 272764, Huntington Beach, California, United States
🇺🇸
West Broward Rheumatology Associates /ID# 272892, Tamarac, Florida, United States
🇺🇸
Dr. Ramesh Gupta /ID# 272897, Memphis, Tennessee, United States

and more 3 locations

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Phase 1

Recruiting

Conditions: Hepatocellular Cancer
Squamous-Cell Non-Small Cell Lung Cancer

Interventions: Drug: ABBV-324
Drug: Lenvatinib

First Posted Date: 2025-03-05

Last Posted Date: 2025-05-13

Lead Sponsor: AbbVie

Target Recruit Count: 232

Registration Number: NCT06858813

Locations: 🇺🇸
City of Hope National Medical Center /ID# 270526, Duarte, California, United States
🇺🇸
City of Hope Orange County Lennar Foundation Cancer Center /ID# 276120, Irvine, California, United States
🇮🇱
Rambam Health Care Campus /ID# 270604, Haifa, H_efa, Israel

and more 3 locations

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

Phase 1

Recruiting

Conditions: Healthy Volunteer

Interventions: Drug: ABBV-932

First Posted Date: 2025-02-27

Last Posted Date: 2025-03-11

Lead Sponsor: AbbVie

Target Recruit Count: 28

Registration Number: NCT06849791

Locations: 🇺🇸
Acpru /Id# 266649, Grayslake, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy